DOCSLIB.ORG

MEDICINAL CHEM ISTRY Q Copyright 1993 by the American Chemical Society

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MEDICINAL CHEM ISTRY Q Copyright 1993 by the American Chemical Society JOURNAL OF MEDICINAL CHEM ISTRY Q Copyright 1993 by the American Chemical Society Volume 36, Number 21 October 15,1993 Pe rspe c t iu e Concepts and Progress in the Development of Peptide Mimetics Gary L. Olson,. David R. Bolin, Mary Pat Bonner, Michael BOs, Charles M. Cook, David C. Fry, Bradford J. Graves, Marcos Hatada, David E. Hill, Michael Kahn, Vincent S. Madison, Victoria K. Rusiecki, Ramakanth Sarabu, Jerry Sepinwall, George P. Vincent, and Matthew E. Voss Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey 07110 Received May 19, 1993 Medicinal chemistry research has been dramatically ology is applicable to enzyme inhibition as well. The broad transformed by biotechnology. Previously, synthetic use of the term “peptide mimetics” is unavoidable, but chemistry and natural products screening dominated drug advocates of rational design do not favor its use to describe research, but now molecular biology has become a driving compounds found by screening. Nevertheless, leads found force behind screening and the establishment of macro- by screening contribute to the understanding of phar- molecular targets. Most of the research in biotech macophores that recognize peptide binding sites. Simi- companies has been directed to peptide and protein larly, natural product opiate alkaloids are frequently cited therapeutics in spite of problems associated with their as examples of peptidomimetics2J because they validate low bioavailability, rapid metabolism, and lack of oral many of the concepts invoked in rational design. In fact, activity. Because of these limitations, research groups they also make a case for how structurally different continue to rely upon chemical synthesis of nonpeptide nonpeptides may be from their peptide parents (lacking substances for drug discovery, recognizing that small flexibility, amide bonds, and obvious pharmacophore molecules are likely to remain the most viable avenue for similarity) and how their modification can lead to highly the identification and optimization of potential drugs. The selective ligands for subtypes of receptors in both peptide challenge is to devise strategies that take advantage of the and nonpeptide c~mpounds.~ strengths of biotechnology to define and characterize Another class of peptide mimetic research that lies molecular targets and of medicinal chemistry to develop between the screening approach and de novo mimetics compounds. A promising approach integrating these design is centered on the replacement of individual peptide disciplines is the field of peptide mimetics, a conceptual bonds by a nonpeptidic These peptide surrogates approach which considers peptides and proteins not as are complemented by the synthesis of peptides incorpo- potential therapeutics but rather as leads for the discovery rating unnatural amino acids, conformational constraints, of other classes of compounds. and larger subunits, for example, dipeptide mimetics. The terms “peptide mimetics” and “peptidomimetics” These compounds bridge the gap between simple peptide have been utilized interchangeably to describe compounds analogs and the completely nonpeptide structures. In this discovered through a variety of research strategies.l respect, they represent a step along the path toward the Indeed, even compounds identified by random screening rationally designed nonpeptide. In many cases, peptide and subsequently optimized through structural modifi- surrogates are likely to be an essential stage in the cation have been termed peptidomimetics if the initial development of a pharmacophoric hypothesis for confor- lead was found in an assay in which the natural ligand is mationally flexible peptides.6 In addition, new technol- a peptide or protein.2 The field of enzyme inhibitors uses ogies for the rapid screening of peptide libraries7 will peptide mimetics terminology for replacements of seg- generate many highly flexible lead structures with modest ments of peptide-based substrates and inhibitors. In this binding affinities. Optimization and eventual translation Perspective, the emphasis will be on mimetics of peptide of a peptide lead to a small molecule drug will probably and protein ligands for receptors, although the method- require isosteric replacements, cyclic peptide derivatives, 0022-2623/93/1836-3039$04.00100 1993 American Chemical Society 3040 Journal of Medicinal Chemistry, 1993, Vol. 36, No. 21 Perspective H Bnoy:o@ En0 +-O(CH,),NHR 6 Figure 2. Somatostatin mimetic 6 (R = H)based on a glucose 0 H-f ternplate.l8 analogous to those of the peptide. Even in protein ligand structures where backbone conformations are known from X-ray crystallography, the side chains involved in inter- action with a receptor may move considerably from their orientation on the crystal surface they dock into 3 4 as recognition sites on the receptor. If a lead activity is seen for a flexible mimetic, adding conformational constraints to side chain groups is then a rational approach to enhance potency and selectivity. 4. Select appropriate targets based on availability of a pharmacophore hypothesis, or develop the information as a first step. Attempting to carry out a peptide mimetic H 0 project on a system for which there is no idea of structure- 5 activity relationships and no three-dimensional hypothesis of the bioactive conformation is irrational. Such a program Figure 1. @-Turnmimetics (1,l12,12 3,13 4,14 P). is likely to generate many inactive compounds and little useful guidance for further work. For systems where the bond surrogates, and conformational constraints as logical biological rationale or medical need is sufficient to justify steps in the process. a peptide mimetics approach, efforts to provide a phar- The rational design of nonpeptide compounds thus is macophore hypothesis as a first step are justified and not feasible without the information obtained from the critical to the outcome of the peptide mimetics programs. study of the structure-activity relationships and confor- Nonpeptide leads designed by this strategy might be mational properties of peptide structures. When such expected to behave more like the structures derived from information is available, and the indication is that the screening synthetic compound collections or natural peptide backbone is not a critical element in receptor products in terms of their bioavailability, metabolic binding,* the design of a nonpeptide becomes feasible. stability, and transport. With an appropriate and suc- The transition to a mimetic can then be made rational by cessful design and subsequent modification of an initial adopting some general principles, adapted from the treatise lead structure, the likelihood that these peptide mimetics of Farmer.g will become drug candidates is high. Progress toward this goal is just beginning to emerge. In this Perspective, we Design Criteria for Peptide Mimetics will describe some of our initial efforts to design peptide 1. Replace as much of the peptide backbone as possible mimetics to constrain secondary structural elements of by a nonpeptide framework. If bond surrogates have been peptides and will review the progress in our first cases of shown to retain activity, or peptide bonds are not exposed de novo design following the basic principles outlined in the presumed bioactive conformation, then a structural above. template may be designed to eliminate amide bonds. 2. Maintain peptide side chain pharmacophoric groups Mimicking Architectural Elements of Protein as in the peptide. Rather than completely dispensing with Structure a relationship between peptide and nonpeptide, initially &Turn Mimetics. Major effortslo have been devoted to designed mimetics may retain groups as found on the the development of templates that mimic or stabilize peptide, as these are most likely to be recognized by a several common architectural elements of peptide and receptor. For example, if a lysine residue is known to be protein structure, Le., &turns, helices, and @-sheets. The required for activity in the peptide, then the first- majority of the @-turn mimetics have been dipeptide generation mimetic should have a primary amino group mimetic replacements for the i + 1 and i + 2 residues at at the end of a methylene chain. As the design progresses the corners of the turn. These have been designed to retain through other generations, amine variants, different chain the intramolecular hydrogen bonding network of an lengths, conformational constraints, and substitutions on appended peptide chain (e.g., Figure 1, compounds 1-4). the nitrogen may be fruitful ways to enhance binding However, these examples lackan appendage for the corner affinity. residue side chains. Since these are the residues that are 3. Retain some conformational flexibility in first- most exposed to the surface of a protein, and most likely generation mimetics. The probability that a pharma- to be involved in intermolecular interactions with a cophore hypothesis will be definitive for flexible peptide receptor, their elimination limits the scope of the mimetic side chains is low, making it necessary that the first designs to that of a group that enforces a conformational constraint. leave some of the side chain pharmacophoric groups While these structures are valuable for answering unconstrained so that they may adopt conformations fundamental questions about protein folding, we felt it Perspective Journal of Medicinal Chemistry, 1993, Vol. 36, No. 21 3041 Scheme I FH3 y3 PW13 H?NOH*HCI N-methyllonnanilide odichlorobenzene CHO ? 81% "GO 1. LAH, THF, reflux - Y Br Br 2. (~%uoco)~o, - dioxane, 5% NaOH NKo-'BuCH2CI2, -10 'C 0 CO, PdC12(PPh3)2 7 m Br o-'Bu PPh3,llO0C "2 MeOH, Bu~N K0 88% 62% 7 0 83% 14 Chart I m Ac-Cys-(-N-Me)Arg-Gly-Asp-Pen-", Gly-Pen-Gly-ArgGIy-Asp-Pro-Cys-Ala 7 8 r-- I Ac-Cys-Asn-Dtc-Amf-Gly-Asp-Cys-OH 0 NH O*COOH 11 10 NH NH 12 (Pen= Penicillamine, Dtc= 5,5-dimethylthiazolidine-4-carboxylicacid, and Amf= p- aminometh ylp henylalanine) 3042 Journul of Medicinal Chemistry, 1993, Vol. 36, No. 21 Perspectiue Figure 3. VIP sequence and critical residues (shadowed). Figure 4. VIP structureby NMR in solution (left, 25 9% MeOH in H20;center, 50% MeOH in HnO;right, superposition showing closely aligned central core).
Load more

Recommended publications
  • Is Chromogranin a Prohormone? Had Only a Fraction of the Pancreastatin Potency of the Peptide Characterized by Lee E
    ~N...:.AT.;:...U=--R.;:...E_V_O_L_.~32_5 _22_J_A_NU_A_R_Y_l_98_7 _________ NEWS ANDVIEWS-------------------'--301 Peptide function small percentage of plasma chromogranin was processed to a pancreastatin-like molecule, or if native chromogranin A Is chromogranin a prohormone? had only a fraction of the pancreastatin potency of the peptide characterized by Lee E. Eiden Tatemoto et at .. It is clearly necessary to establish that the molecule isolated by IN THE 4 December issue of Nature!, K. terminal processing signal for the forma- Tatemoto et at. is indeed the substance Tatemoto and co-workers report the tion of pancreastatin from a chromogranin found at beta-cell and D-cell receptors in sequence of a newly discovered putative A-like precursor in the rat. vivo. It will be of special interest to deter- hormone, pancreastatin, which as its There is chromogranin, as well as mine if amidation is necessary for bio­ name implies inhibits insulin (and soma­ pancreastatin, immunoreactivity in the logical activity, because amidation of tostatin) secretion from the endocrine pancreas of several species, and both poly- other biologically active peptides such as pancreas. There is a striking structural peptides are present in the brain"!', consis- enkephalins seems to oc-cur differentially similarity between pancreastatin and part tent with a precursor-product relationship in central and autonomic nervous tissue, of bovine chromogranin A, whose se­ between chromogranin A and pancreas- and this differential post-translational quence was recently reported in Nature by tatin. Whether or not pancreastatin is gen- modification may be relevant to different, myself and collaborators, and independ­ erated from chromogranin A or a chromo- as yet undiscovered hormonal functions of ently in the EMBO Journal by Benedum granin A-like precursor must await the these molecules.
    [Show full text]
  • Thiol-Disulfide Exchange in Human Growth Hormone Saradha Chandrasekhar Purdue University
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations January 2015 Thiol-Disulfide Exchange in Human Growth Hormone Saradha Chandrasekhar Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Recommended Citation Chandrasekhar, Saradha, "Thiol-Disulfide Exchange in Human Growth Hormone" (2015). Open Access Dissertations. 1449. https://docs.lib.purdue.edu/open_access_dissertations/1449 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. i THIOL-DISULFIDE EXCHANGE IN HUMAN GROWTH HORMONE A Dissertation Submitted to the Faculty of Purdue University by Saradha Chandrasekhar In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy August 2015 Purdue University West Lafayette, Indiana ii To my parents Chandrasekhar and Visalakshi & To my fiancé Niranjan iii ACKNOWLEDGEMENTS I would like to thank Dr. Elizabeth M. Topp for her tremendous support, guidance and valuable suggestions throughout. The successful completion of my PhD program would not have been possible without her constant encouragement and enthusiasm. Through the last five years, I’ve learned so much as a graduate student in her lab. My thesis committee members: Dr. Stephen R. Byrn, Dr. Gregory T. Knipp and Dr. Weiguo A. Tao, thank you for your time and for all your valuable comments during my oral preliminary exam. I would also like to thank Dr. Fred Regnier for his suggestions with the work on human growth hormone. I am grateful to all my lab members and friends for their assistance and support. I would like to especially thank Dr.
    [Show full text]
  • A Process for Producing Human Growth Hormone
    Patentamt JEuropaischesEuropean Patent Office (in Publication number: 0 217 814 Office europeen des brevets B1 EUROPEAN PATENT SPECIFICATION Date of publication of patent specification: 16.05.90 int.ci.5: C 12 P 21/06, C 12 N 15/00 Application number: 86901361.5 Date of filing: 06.02.86 International application number: PCT/DK86/00014 International publication number: WO 86/04609 14.08.86 Gazette 86/18 A PROCESS FOR PRODUCING HUMAN GROWTH HORMONE. (§) Priority: 07.02.85 DK 556/85 Proprietor: NOVO-NORDISK A/S Novo Alle DK-2880 Bagsvaerd (DK) Date of publication of application: 15.04.87 Bulletin 87/16 Inventor: ANDERSEN, Henrik, Dalboge Ordrupvej 1 12 B Publication of the grant of the patent: DK-2920 Charlottenlund (DK) 16.05.90 Bulletin 90/20 Inventor: PEDERSEN, John Kajerodvaenge 35 DK-3460 Birkero /d (DK) Designated Contracting States: Inventor: CHRISTENSEN, Thorkild AT BE CH DE FR GB IT LI LU NL SE Bellisvej 55 DK-3450Allerod(DK) Inventor: HANSEN, Jorli, Winnie References cited: Kloverhoj20 EP-A-0020290 DK-2600Glostrup(DK) EP-A-0089626 Inventor: JESSEN, Torben, Ehlern WO-A-84/02351 Kalundborgvej 216 US-A-4543329 DK-4300Holbaek(DK) Chemical Abstracts, vol. 77, 1972, Abstract no. 2289q, Calluhan et al, Fed. Proc. Fed. Amer, Coc. Representative: von Kreisler, Alek, Dipl.-Chem. Exp. Biol. 1972 31(3), 1105-13 (Eng). etal 00 Deichmannhaus am Hauptbahnhof Chemical Abstracts, vol. 76, 1972, Abstract no. D-5000 Koln 1 (DE) 83215s, Lindley et al. Biochem J. 1972. 126(3), 683-5(Eng). O Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Evidence That the Major Degradation Product of Glucose-Dependent Insulinotropic Polypeptide, GIP(3–42), Is a GIP Receptor Antagonist in Vivo
    525 Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3–42), is a GIP receptor antagonist in vivo V A Gault, J C Parker, P Harriott1, P R Flatt and F P M O’Harte School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, N Ireland BT52 1SA, UK 1Centre for Peptide and Protein Engineering, School of Biology and Biochemistry, The Queen’s University of Belfast, Medical Biology Centre, Belfast, N Ireland BT9 7BL, UK (Requests for offprints should be addressed to V A Gault; Email: [email protected]) Abstract The incretin hormone glucose-dependent insulinotropic was significantly less potent at stimulating insulin secretion polypeptide (GIP) is rapidly degraded in the circulation (1·9- to 3·2-fold; P<0·001), compared with native GIP by dipeptidyl peptidase IV forming the N-terminally and significantly inhibited GIP-stimulated (107 M) truncated peptide GIP(3–42). The present study exam- insulin secretion with maximal inhibition (48·86·2%; ined the biological activity of this abundant circulating P<0·001) observed at 107 M. In (ob/ob) mice, admin- fragment peptide to establish its possible role in GIP istration of GIP(3–42) significantly inhibited GIP- action. Human GIP and GIP(3–42) were synthesised stimulated insulin release (2·1-fold decrease; P<0·001) and by Fmoc solid-phase peptide synthesis, purified by exaggerated the glycaemic excursion (1·4-fold; P<0·001) HPLC and characterised by electrospray ionisation-mass induced by a conjoint glucose load. These data indicate spectrometry. In GIP receptor-transfected Chinese ham- that the N-terminally truncated GIP(3–42) fragment acts ster lung fibroblasts, GIP(3–42) dose dependently inhib- as a GIP receptor antagonist, moderating the insulin ited GIP-stimulated (107 M) cAMP production (up to secreting and metabolic actions of GIP in vivo.
    [Show full text]
  • V1-Vasopressin Antagonists
    Europaisches Patentamt ® 0 1 82 626 � European Patent Office © Publication number: Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION © Application number: 85308325.1 © Int. CI.4: C07K 7/06 , C07K 7/1 6 , A61 K 37/02 (g)rs Date of filing: 15.11.85 ® Priority: 21.11.84 US 673828 © Applicant: SMITHKLINE BECKM AN CORPORATION P.O. Box 7929 1 Franklin Plaza © Date of publication of application: Philadelphia Pennsylvania 191 01 (US) 28.05.86 Bulletin 86/22 © Inventor: Ali, Fadia Elfehail © Designated Contracting States: 5 Green Acre Drive, N. AT BE CH DE FR GB IT LI LU NL SE Cherry Hill New Jersey 08003(US) Inventor: Huffman, William Francis 40 Crest Avenue Malvern Pennsylvania 19355(US) © Representative: Waters, David Martin, Dr. et al Smith Kline & French Laboratories Ltd. Patent De- partment Mundells Welwyn Garden City Hertfordshire AL7 1EY(GB) © V1 -vasopressin antagonists. Compounds having the formula: in which: or a pharmaceutically acceptable salt thereof, which have V,-vasopressin antagonist activity and which are useful in the treatment of hypertension, shock and cardiac insuffi- P is Phe, Ile, Phe(4'-Alk), Tyr or Tyr(Alk); ciency. X is a D or L isomer of Val, Nva, Leu, Ile, Pba, Phe, Phe(4'-Alk), Trp, Nle, Cha, Abu, Met, Chg, Tyr or Tyr(Alk); Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Thr, Nle, Phe, Leu or Gly; Z is a D or L isomer of Arg, Harg, Leu, Lys or Orn; A is Gly(NH,), Gly, Gly(NH-Alk), OH, NH, or NHAlk; and R is, each, hydrogen or methyl; This invention relates to cyclic peptides which have studied, the β,β-diethyl and β,β-cyclopentamethylene pro- vasopressin (VSP) antagonist activity.
    [Show full text]
  • Page 1 of 30 Food & Function
    Food & Function Accepted Manuscript This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/foodfunction Page 1 of 30 Food & Function Novelty of work In vitro transport of β-CM7 is limited by rapid hydrolysis into three peptide metabolites that transport at variable rates. 3.0 * 2.5 * * 2.0 * 1.5 1.0 * Manuscript Ratio to basal CCK-8 secretion CCK-8 basal to Ratio 0.5 0.0 M M M M M M M M M M M M M 500 250 125 500 250 125 500 250 125 1000 1000 1000 Fig. 8. Secretion of cholecystokinin[26-33] (CCK-8) by STC-1 cells in response to decreasing Accepted concentrations of YL and β-CM7 , compared to HBSS (basal) control .
    [Show full text]
  • Effect of Homochirality of Dipeptide to Polymers' Degradation
    polymers Article Effect of Homochirality of Dipeptide to Polymers’ Degradation Xinqiang Xu 1,2, Fuyan He 1,2, Wenke Yang 1,2 and Jinshui Yao 1,2,* 1 School of Materials Science & Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China; [email protected] (X.X.); [email protected] (F.H.); [email protected] (W.Y.) 2 Shandong Provincial Key Laboratory of Processing & Testing Technology of Glass and Functional Ceramics, Jinan 250353, China * Correspondence: [email protected] Received: 31 August 2020; Accepted: 18 September 2020; Published: 22 September 2020 Abstract: As natural polymer materials, proteins are readily biodegradable, interestingly, the synthetic polyamides (PAs) that are based on the same amide bonds (also called peptide bonds in proteins) are barely degradable. Whether did the chirality and configuration of the amino acids play an important role. By using different configuration of amino acids, 4 types of polyamide-imides (PAIs) containing dipeptides of LL, DL, LD, and DD configurations, respectively, were synthesized. It was found that the PAIs based on natural LL configuration of dipeptide structure are much more readily biodegradable than those based on non-natural LD, DL, and DD configuration of dipeptides. It was confirmed that the natural L-configuration of amino acids play a critical role in degradability of proteins. And it also suggested that different type and amount of peptide fragments can be introduced in polymer to create series of polymer materials that can be biodegraded at controllable speed. Keywords: chiral amino acids; dipeptide; polyamide-imides; biodegradability 1. Introduction With the growing problem of white pollution, degradable polymer materials are attracting more and more attention because polymer materials that can be degraded at controllable speed could be used in every kind of fields [1–6].
    [Show full text]
  • Gastrin-Releasing Peptide (Grp)/Bombesin-Like Immunoreactivity in the Neurons and Paraneurons of the Gut and Lung
    Biomedical Research 4 (1) 93-104, 1983 GASTRIN-RELEASING PEPTIDE (GRP)/BOMBESIN-LIKE IMMUNOREACTIVITY IN THE NEURONS AND PARANEURONS OF THE GUT AND LUNG TOSHIHIKO IWANAGA Department of Anatomy, Niigata University School of Medicine, Niigata 951, Japan ABSTRACT Gastrin-releasing peptide (GRP)/bombesin-like immunoreactivities in the gut and lung were investigated with an immunocytochemical method using antisera showing different specificity for GRP-related peptides and bombesin. GRP-like, but not bombesin-like, immunoreactivity in the gut of birds and frogs was contained in the endocrine cells, which were restricted mainly to the oxyntic mucosa. On the other hand, GRP immunoreactivity in the rat and swine gut was contained in the nerve fibers distributed in the gastric mucosa and in the submucosal and myenteric plex- uses of the gut wall. In the lungs of human fetuses, the endocrine cells, solitary or gathered in groups, were immunoreactive to the GRP antisera. These endocrine cells and nerve fibers in the gut and lung showed the same immunoreactivity to two GRP antisera, but not to a bombesin-specific antiserum. This suggests that the bombesin- like immunoreactivities reported in the previous studies may be due to the existence of GRP or GRP-related peptides. Electron microscopic immunocytochemistry revealed that the GRP-like immunoreactivity was localized in the cytoplasmic gran- ules of the pulmonary endocrine cells and in the dense-cored vesicles of the gut nerve fibers. Bombesin is a tetradecapeptide isolated from the resides in the C-terminal portion of the molecule skin of Bombina bombina and Bombina variegara (17). Moreover, a heptacosapeptide having (1).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,097.590 B2 Pinel Et Al
    USO08097590B2 (12) United States Patent (10) Patent No.: US 8,097.590 B2 Pinel et al. (45) Date of Patent: Jan. 17, 2012 (54) o-MSH-ANTAGONIST DIPEPTIDE FOREIGN PATENT DOCUMENTS CONUGATES EP O 389 95.0 A1 10, 1990 EP O 669938 B1 9, 1995 (75) Inventors: Anne-Marie Pinel, Toulouse (FR): E. : 29: R 1928 Pascal Verdie, Saint Mathieu de Treviers EP 1174 437 A1 1, 2002 (FR); Pascaline Dubs, Montpellier (FR): FR 1327363 5, 1962 Jean Martinez, Caux (FR); Gilles FR 2805744 A1 9, 2001 Subra, Juvignac (FR) FR 2810 323 A1 12/2001 s GB 1 OOO 897 8, 1965 (73) Assignees: Centre National de la Recherche W. W. 2.95. A. 3E Scientifique (CNRS), Paris (FR): WO WO 98.25584 A1 6, 1998 Institut Europeen de Biologie W. W. 9.3. A. 358: Cellulaire, Ramonville St. Agne (FR): WO WO O2/O85925 A2 10, 2002 Universite de Montpellier I, WO WO 03/064.458 A2 8, 2003 Montpellier (FR); Universite de WO WOO3,O95474 A2 11/2003 Montpellier II, Montpellier (FR) WO WO 2004/099237 A1 11, 2004 WO WO 2004/110341 A2 12/2004 (*) Notice: Subject to any disclaimer, the term of this WO WO 2005,116068 A1 12/2005 patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 1143 days. Stverteczky et al., Acta Chimica Academiae Scientiarum (21) Appl. No.: 11/596,286 Hungaricae, 1975, vol. 87, No. 3, pp. 269-283.* Baumann et al., “Specificity of O-chyrinotrypsin dipeptide Sub (22) PCT Filed: May 10, 2005 strates.” FEBS Letters, Jun.
    [Show full text]
  • United States Patent Office Patented June 19, 1973
    3,740,385 United States Patent Office Patented June 19, 1973 1. 2 R-His-Ser-Asp-Gly 3,740,385 !-- N-TERMINAL DERVATIVES OF SECRETN Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg Miguel Angel Ondetti, 265 Hamlin Road, Leu-Arg-Asp-Ser-Ala-Arg-Leu-Glu(NH2)- North Brunswick, N.J. 08902 No Drawing. Continuation-in-part of abandoned applica Arg-Leu-Leu-Glu(NH2)-Gly-Leu-Val-NH2 tion Ser. No. 827,962, May 26, 1969. This application J. May 7, 1970, Ser. No. 35,598 R1-secretin Int. C. C07c 103/52, C07g 7/00 U.S. C. 260-112.5 6 Claims wherein R1 is a carboxylic acid, an amino acid, or a 10 dipeptide. The above equation takes into consideration that the ABSTRACT OF THE DISCLOSURE proper protection of the required moieties is followed. Disclosed herein are novel N-terminal derivatives of In addition when an acid is utilized, the desired acid the peptide secretin, intermediates thereof and a process may be reacted with secretin according to the equation: for their preparation. The secretin derivative of this in 5 vention are useful as antacids in hyperacidic conditions R2-COX--Secretin->R-CO-Secretin of the stomach and duodenum. wherein R2 is lower alkyl (e.g., methyl, ethyl, isopropyl, RELATED APPLICATION hexyl), aryl (e.g., phenyl or naphthyl), substituted phenyl 20 (e.g., o-chlorophenyl, p-ethylphenyl, m-trifluoromethyl This application is a continuation-in-part of my co phenyl, m-nitrophenyl), aralkyl (e.g., benzyl or phen pending application Ser. No. 827,962 filed May 26, 1969, ethyl), lower alkoxy (e.g., methoxy, ethoxy, butyloxy or now abandoned.
    [Show full text]
  • Development of Dipeptide Transport in the Intestinal Mucosa of Rabbits
    Pediatr. Res. 16: 99-103 (1982) Development of Dipeptide Transport in the Intestinal Mucosa of Rabbits STEFAN0 GUANDALINI'32' AND ARMIDO RUBINO Child Health Institute, 2nd School of Medicine, University of Naples, Italy Summary other hand, they can also be hydrolyzed at the brush border membrane, with-subsequent entjof the released amino acids. The uptake of 0.5 mM glycyl-L-proline (Gly-Pro), a substrate We had previously shown (24) that both ways do occur also in which has affinity for the dipeptide specific carrier system and is in the small intestine of the newborn rabbit, the transport of intact not hydrolyzed in the brush border, was studied vitro in jejunum dipeptide being quantitatively approximately as important as the and ileum of rabbits from the 25th day of gestational age into other pathway. We thus moved to investigate, in the developing adulthood. For comparison, uptake of 0.5 mM glycine was studied rabbit, the carrier system for dipeptides, with these major aims: too. Results show that influx of Gly-Pro is present from the (1) provide a biologic characterization of the system as for sub- earliest age studied and show a steep prenatal increase and peaks straie specificity, ~a dependence and kinetic constants; (2) define f at birth, with values, in the newborn jejunum, of 45.2 3.3 pmoles/ its developmental pattern as compared to that of the uptake of a ghr (mean + S.E.). Thereafter, the uptake slowly declines toward free neutral amino acid, as to provide an ontogenetic basis for the the adult level of 3.8 f 0.5 pmoles/ghr.
    [Show full text]
  • Fish Derived Bio-Active Peptides and Their Metabolic Effects Balık Kaynaklı Biyo-Aktif Peptidler Ve Metabolik Etkileri
    http://www.egejfas.org Su Ürünleri Dergisi (2015 Ege J Fish Aqua Sci 32(4): 217-223 (2015) DOI: 10.12714/egejfas.2015.32.4.08 REVIEW DERLEME Fish derived bio-active peptides and their metabolic effects Balık kaynaklı biyo-aktif peptidler ve metabolik etkileri Can Altınelataman1* • Anna Torkova2 • Mikhail Tsentalovich2 1Ege University, Faculty of Fisheries, 35100, Bornova, İzmir, Turkey 2Federal State Institution, Federal Research Centre, Fundamentals of Biotechnology of the Russian Academy of Sciences, Biochemistry Institute of Russian Academy of Sciences, Moscow, Russia *Corresponding Author: [email protected] How to cite this paper: Altınelataman, C., Torkova, A., Tsentalovich, M., 2015. Fish derived bio-active peptides and their metabolic effects. Ege J Fish Aqua Sci 32(4): 217-223. doi: 10.12714/egejfas.2015.32.4.08 Özet: Diğer tüm organizmalar gibi, balıklar da, araştırmalarda antimikrobiyal, antihipertensif, antioksidan ve antitümör aktivitelerine odaklanılan bio-aktif bileşiklerin zengin kaynağıdırlar. Bunlar, sadece yüksek besin değeri nedeniyle değil, özellikle son yirmi yılda geliştirilen analitik yöntemlerle elde edilen peptidleri açısından da kullanılabilirler. Akuatik canlılar dünya üzerinde en fazla tür sayısına sahiptir, dolayısıyla bunlardan bio-aktif peptidlerin eldesi diğerlerine göre oldukça olasıdır ve bu, önceki çalışmalarda açıkça ortaya konmuştur. Doğal peptidler ve uzun zincirli polipeptidlerden uygun enzimatik yöntemlerle elde edilen peptidler tıp alanında yeni ufuklar açabilirler. Anahtar kelimeler: Balık, peptidler, bio-aktif, metabolik etki, sağlık Abstract: Like many other organisms, fishes are also rich sources of bio-active compounds which were well studied by research focused on their antimicrobial, antihypertensive, antioxidant and antitumor activities. They can be used not only for good nutritional value, but also for peptides obtained with analytic processes that were developed in last decades.
    [Show full text]